Acromegaly and thyroid cancer: analysis of evolution in a series of patients.

Karina Danilowicz, Soledad Sosa, Mariana Soledad Gonzalez Pernas, Elizabeth Bamberger, Sabrina Mara Diez, Patricia Fainstein-Day, Alejandra Furioso, Mariela Glerean, Mirtha Guitelman, Débora Katz, Nicole Lemaitre, Alicia Lowenstein, Mariela Del Valle Luna, María Paz Martínez, Karina Miragaya, Daniel Moncet, María Victoria Ortuño, Analía Pignatta, Constanza Fernanda Ramacciotti, Adriana Reyes, Amelia Susana Rogozinski, Patricia Slavinsky, Julieta Tkatch, Fabián Pitoia
{"title":"Acromegaly and thyroid cancer: analysis of evolution in a series of patients.","authors":"Karina Danilowicz,&nbsp;Soledad Sosa,&nbsp;Mariana Soledad Gonzalez Pernas,&nbsp;Elizabeth Bamberger,&nbsp;Sabrina Mara Diez,&nbsp;Patricia Fainstein-Day,&nbsp;Alejandra Furioso,&nbsp;Mariela Glerean,&nbsp;Mirtha Guitelman,&nbsp;Débora Katz,&nbsp;Nicole Lemaitre,&nbsp;Alicia Lowenstein,&nbsp;Mariela Del Valle Luna,&nbsp;María Paz Martínez,&nbsp;Karina Miragaya,&nbsp;Daniel Moncet,&nbsp;María Victoria Ortuño,&nbsp;Analía Pignatta,&nbsp;Constanza Fernanda Ramacciotti,&nbsp;Adriana Reyes,&nbsp;Amelia Susana Rogozinski,&nbsp;Patricia Slavinsky,&nbsp;Julieta Tkatch,&nbsp;Fabián Pitoia","doi":"10.1186/s40842-020-00113-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acromegaly is associated with higher morbidity and mortality mainly due to cardiovascular disease. Data on the incidence and evolution of thyroid cancer in acromegaly are controversial. Our objective was to describe the characteristics of a group of acromegalic patients with differentiated thyroid carcinoma (DTC) and analyze their evolution.</p><p><strong>Methods: </strong>This is a retrospective multicenter study of 24 acromegalic patients with DTC. The AJCC Staging System 8th Edition was used for TNM staging, and the initial risk of recurrence (RR), initial response and response at the end of follow-up (RFU) were defined according to the 2015 ATA Guidelines. As a control group, 92 patients with DTC without acromegaly were randomly included. Statistical analyses were done using SPSS Statistics 20.0.</p><p><strong>Results: </strong>Median age of patients at diagnosis of acromegaly was 49.5 years (range 12-69). The median delay in diagnosis of acromegaly was 3 years (range 0.5-23). Mean baseline IGF-1 level was 2.9 ± 1.1 ULN. Median age at DTC diagnosis was 51.5 years (18-69). At the moment of diagnosis of DTC, 58.3% of the patients had active acromegaly. Median time from DTC diagnosis to acromegaly control was 1.25 years (0.5-7). Mean DTC tumor diameter of the biggest lesion was 14.6 ± 9.2 mm, being multifocal in 37.5%. All tumors were papillary carcinomas, two cases being of an aggressive variety. Lymph node dissection was performed in 8 out of 24 patients and 62.5% had metastases. Only one patient had distant metastases. Radioiodine ablation was given to 87.5% of patients. Nineteen patients (79%) were stage I, four (17%) stage II and one (4%) stage IVb. Initial RR was low in 87% (21/24), intermediate in 9% (2/24) and high in 4% (1/24) patient. RFU was: 83% (19/23) patients with no evidence of disease, 9% (2/23) with indeterminate response, 4% (1/23) with biochemical incomplete response and 4% (1/23) with structural incomplete response, at a median time of FU of 36.5 months. When comparing RFU between acromegalics and controls no statistically significant differences were found.</p><p><strong>Conclusions: </strong>Patients with acromegaly and DTC mostly had a low initial RR. When compared with the control group, we found that DTC patients with acromegaly did not have a worse evolution.</p>","PeriodicalId":56339,"journal":{"name":"Clinical Diabetes and Endocrinology","volume":"6 1","pages":"24"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40842-020-00113-4","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes and Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40842-020-00113-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Background: Acromegaly is associated with higher morbidity and mortality mainly due to cardiovascular disease. Data on the incidence and evolution of thyroid cancer in acromegaly are controversial. Our objective was to describe the characteristics of a group of acromegalic patients with differentiated thyroid carcinoma (DTC) and analyze their evolution.

Methods: This is a retrospective multicenter study of 24 acromegalic patients with DTC. The AJCC Staging System 8th Edition was used for TNM staging, and the initial risk of recurrence (RR), initial response and response at the end of follow-up (RFU) were defined according to the 2015 ATA Guidelines. As a control group, 92 patients with DTC without acromegaly were randomly included. Statistical analyses were done using SPSS Statistics 20.0.

Results: Median age of patients at diagnosis of acromegaly was 49.5 years (range 12-69). The median delay in diagnosis of acromegaly was 3 years (range 0.5-23). Mean baseline IGF-1 level was 2.9 ± 1.1 ULN. Median age at DTC diagnosis was 51.5 years (18-69). At the moment of diagnosis of DTC, 58.3% of the patients had active acromegaly. Median time from DTC diagnosis to acromegaly control was 1.25 years (0.5-7). Mean DTC tumor diameter of the biggest lesion was 14.6 ± 9.2 mm, being multifocal in 37.5%. All tumors were papillary carcinomas, two cases being of an aggressive variety. Lymph node dissection was performed in 8 out of 24 patients and 62.5% had metastases. Only one patient had distant metastases. Radioiodine ablation was given to 87.5% of patients. Nineteen patients (79%) were stage I, four (17%) stage II and one (4%) stage IVb. Initial RR was low in 87% (21/24), intermediate in 9% (2/24) and high in 4% (1/24) patient. RFU was: 83% (19/23) patients with no evidence of disease, 9% (2/23) with indeterminate response, 4% (1/23) with biochemical incomplete response and 4% (1/23) with structural incomplete response, at a median time of FU of 36.5 months. When comparing RFU between acromegalics and controls no statistically significant differences were found.

Conclusions: Patients with acromegaly and DTC mostly had a low initial RR. When compared with the control group, we found that DTC patients with acromegaly did not have a worse evolution.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肢端肥大症与甲状腺癌:一系列患者的进化分析。
背景:肢端肥大症的发病率和死亡率较高,主要由心血管疾病引起。肢端肥大症中甲状腺癌的发病率和发展数据存在争议。我们的目的是描述一组肢端肥大症患者分化甲状腺癌(DTC)的特点,并分析其演变。方法:对24例肢端肥大症合并DTC患者进行回顾性多中心研究。采用AJCC分期系统第8版进行TNM分期,根据2015年ATA指南定义初始复发风险(RR)、初始缓解和随访末缓解(RFU)。随机选取92例无肢端肥大的DTC患者作为对照组。采用SPSS Statistics 20.0进行统计学分析。结果:肢端肥大症患者的中位年龄为49.5岁(范围12-69岁)。肢端肥大症的诊断延迟中位数为3年(范围0.5-23年)。平均基线IGF-1水平为2.9±1.1 ULN。DTC诊断的中位年龄为51.5岁(18-69岁)。在诊断为DTC时,58.3%的患者有活动性肢端肥大症。从DTC诊断到肢端肥大症控制的中位时间为1.25年(0.5-7年)。DTC最大病灶平均直径14.6±9.2 mm,多灶性占37.5%。所有肿瘤均为乳头状癌,其中2例为侵袭性肿瘤。24例患者中有8例进行了淋巴结清扫,62.5%发生了转移。只有一名患者有远处转移。87.5%的患者接受了放射性碘消融治疗。19例患者(79%)为I期,4例(17%)为II期,1例(4%)为IVb期。初始RR低的占87%(21/24),中等的占9%(2/24),高的占4%(1/24)。RFU患者中:83%(19/23)无疾病证据,9%(2/23)反应不确定,4%(1/23)生化不完全缓解,4%(1/23)结构不完全缓解,FU的中位时间为36.5个月。肢端肥大症患者的RFU与对照组比较,差异无统计学意义。结论:肢端肥大症合并DTC患者的初始RR均较低。与对照组相比,我们发现伴有肢端肥大症的DTC患者并没有更差的进化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
7
审稿时长
8 weeks
期刊介绍: Clinical Diabetes and Endocrinology is an open access journal publishing within the field of diabetes and endocrine disease. The journal aims to provide a widely available resource for people working within the field of diabetes and endocrinology, in order to improve the care of people affected by these conditions. The audience includes, but is not limited to, physicians, researchers, nurses, nutritionists, pharmacists, podiatrists, psychologists, epidemiologists, exercise physiologists and health care researchers. Research articles include patient-based research (clinical trials, clinical studies, and others), translational research (translation of basic science to clinical practice, translation of clinical practice to policy and others), as well as epidemiology and health care research. Clinical articles include case reports, case seminars, consensus statements, clinical practice guidelines and evidence-based medicine. Only articles considered to contribute new knowledge to the field will be considered for publication.
期刊最新文献
Does EFSA statement on Monacolin content of nutraceutical combinations impair their lipid lowering effect? The LopiGLIK experience. Propylthiouracil-induced vasculitis with alveolar hemorrhage after 31 years of treatment: a case report. The impact of insulin resistance and glycaemic control on insulin-like growth factor-1 in patients with type 2 diabetes: a cross-sectional study. Metanephrine mirage: distinguishing the phaeocopies, a case report and literature review. Microbial profile of diabetic foot osteomyelitis from the northwest of England.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1